| |
Group 1
(N = 117)
|
Group 2
(N = 119)
|
Group 3
(N = 114)
|
|---|
|
Sex, n (%)
|
|
Female
|
57 (48.7)
|
61 (51.3)
|
58 (50.9)
|
|
Age, years
|
|
Mean (SD)
|
31.8 (7.7)
|
32.6 (7.3)
|
32.8 (7.6)
|
|
Racial origin
|
|
White Caucasian
|
88 (75.2)
|
103 (86.6)
|
88 (77.2)
|
|
Black or African American
|
21 (17.9)
|
14 (11.8)
|
19 (16.7)
|
|
Other
|
8 (6.8)
|
2 (1.7)
|
7 (6.1)
|
|
Seropositivity status, n (%)a
|
|
Dengue seropositive
|
9 (7.7)
|
9 (7.6)
|
8 (7.0)
|
|
Yellow fever seropositiveb
|
59 (50.4)
|
61 (51.3)
|
6 (5.3)
|
|
Flavivirus seropositive
|
63 (53.8)
|
65 (54.6)
|
11 (9.6)
|
- n number of participants with the specified characteristic, N total number of participants in the study group, SD standard deviation
- aParticipants were defined as dengue or YF seropositive if they had neutralising antibody titres > 10 1/dilution (for at least one serotype for dengue seropositivity); participants were considered FV seropositive if they were seropositive for dengue of YF, or both
- bParticipants were randomised to treatment groups with stratification on prior reported YF vaccination (in the 3 months to 10 years preceding first study vaccine dose), such that 50% of Group 1 and 2 participants and no participants in Group 3 had prior reported YF. Laboratory confirmation of YF seropositive status according to protocol revealed discrepancies between the YF PRNT50 assay and the reported YF vaccination history; the YF seropositive status of participants at baseline was thus re-calculated using YF PRNT80, a more stringent assay compared to YF PRNT50. Results based on PRNT80 are shown for YF and FV seropositive status
